Anuh Pharma Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹819 Cr
- P/E
- 17.15
- ROE
- 11.32%
- PEG
- 3.27
- Price to sales
- 1.05
- Debt to equity
- 0.05
- 52W high / low
- ₹96.7 / ₹67.0
- Sales growth (5Y)
- 12.30%
- EBITDA margin
- 9.28%
- Net profit margin
- 4.97%
- Promoter holding
- 71.79%
- Sales (last year)
- ₹778 Cr
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals[1]
Guidance scorecard · Q2 FY27 call
What Anuh Pharma's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ4 FY22 call
10–20%- The company targets sales of Rs. 600 crores for FY 2023, showing optimism about demand resumption despite currently falling short.
- Plans to introduce five new API products in FY23: Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine, to build growth foundation.
- Focus on increasing market share of existing products and geographic expansion in Vietnam, Japan, and South Korea.
- Approval filings (CEP for Gliclazide, Azithromycin and WHO PQ for Isoniazide) expected to open European market and institutional business, potentially adding Rs. 50 crore in sales within two years post-approval.
- Manufacturing capacity utilization is about 60%, with potential to add 300 tons capacity by machinery addition.
2 more points from Anuh Pharma's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY22 call
FlatSee what Anuh Pharma said on margins — free account, 30 seconds.
CapexQ4 FY22 call
Planned- The company plans capital expenditure of approximately Rs. 40 to 50 lakhs in FY23 to bring versatility in production capabilities by adding machinery.
- They have previously made CAPEX of Rs. 70 crores in 2019, which expanded manufacturing capacity to 1500 tons; currently utilizing about 60% of this capacity.
- Company focuses on R&D and plans to introduce five new API products in FY23 (Allopurinol, Acebrophylline, Citicoline, Theophylline, and Caffeine) to build a foundation for future growth.
FundraisingQ4 FY22 call
See what Anuh Pharma said on fundraising — free account, 30 seconds.
Order bookQ4 FY22 call
Ask what Anuh Pharma said on the order book →
Full Q4 FY22 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Anuh Pharma latest results (Sep 2026)
Revenue
₹185 Cr
+0% YoY
Net profit
₹11 Cr
+38% YoY
Operating margin
9%
EPS
₹1.12
Anuh Pharma shareholding (Sep 2026)
Promoters
71.79%
unchanged QoQ
FIIs
0.11%
+0.10 pp QoQ
DIIs
0.00%
unchanged QoQ
Public
28.07%
−0.12 pp QoQ
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,041 Cr | 33.1 | |
| 2 | 40%+ | Up 2%+ | ₹492 Cr | 19.6 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,347 Cr | — | |
| 5 | 40%+ | Flat | ₹8,432 Cr | 32.4 | |
| 6 | 40%+ | Flat | ₹4,295 Cr | — |
Sign up free to see every company in the sector ranking and track Anuh Pharma.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Anuh Pharma
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Anuh Pharma
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 69.94% | 69.91% | 69.91% | 69.91% | 69.91% | 69.91% | 69.91% | 71.81% | 71.81% | 71.79% | 71.79% | 71.79% |
| FIIs + | 0.00% | 0.03% | 0.03% | 0.02% | 0.02% | 0.04% | 0.04% | 0.00% | 0.00% | 0.05% | 0.01% | 0.11% |
| DIIs + | 0.00% | 0.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public + | 30.05% | 29.96% | 30.05% | 30.06% | 30.07% | 30.04% | 30.04% | 28.19% | 28.17% | 28.14% | 28.19% | 28.07% |
| No. of Shareholders | 20,519 | 22,237 | 23,494 | 23,910 | 24,279 | 24,235 | 24,257 | 28,250 | 27,889 | 27,425 | 27,484 | 28,447 |
Financials of Anuh Pharma
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 150 | 172 | 164 | 138 | 166 | 160 | 198 | 186 | 186 | 197 | 202 | 194 | 185 |
| YoY Sales growth | +30% | +24% | +4% | -15% | +11% | -7% | +21% | +35% | +12% | +24% | +2% | +4% | -0% |
| Expenses + | 132 | 148 | 145 | 127 | 149 | 145 | 179 | 176 | 174 | 178 | 182 | 178 | 168 |
| Operating Profit | 18 | 24 | 19 | 11 | 17 | 15 | 19 | 10 | 12 | 19 | 20 | 16 | 17 |
| OPM % | 12% | 14% | 12% | 8% | 10% | 9% | 9% | 6% | 6% | 10% | 10% | 8% | 9% |
| Other Income + | 2 | 4 | 3 | 4 | 3 | 1 | 1 | 3 | 1 | 2 | -1 | 3 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 2 |
| Profit before tax | 18 | 25 | 20 | 12 | 18 | 13 | 17 | 11 | 10 | 18 | 16 | 17 | 15 |
| Tax % | 23% | 24% | 22% | 22% | 17% | 22% | 28% | 24% | 23% | 25% | 25% | 32% | 25% |
| Net Profit + | 14 | 19 | 15 | 10 | 15 | 10 | 12 | 8 | 8 | 13 | 12 | 11 | 11 |
| EPS in Rs | 1.38 | 1.91 | 1.53 | 0.95 | 1.50 | 1.03 | 1.24 | 0.83 | 0.76 | 1.34 | 1.17 | 1.14 | 1.12 |
Financials of Anuh Pharma
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 772 | 778 |
| Sales growth | +7% | +15% | -37% | +16% | +35% | -4% | +41% | +13% | +8% | +23% | +2% | +17% | +7% |
| Expenses + | 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 709 | 706 |
| Operating Profit | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 62 | 72 |
| OPM % | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 8% | 9% |
| Other Income + | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 4 | 4 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 11 | 11 |
| Profit before tax | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 54 | 65 |
| Tax % | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | 24% | |
| Net Profit + | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 41 | 48 |
| EPS in Rs | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 4.10 | 4.77 |
| Dividend Payout % | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% | 37% |
Financials of Anuh Pharma
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 | 50 |
| Reserves | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 302 | 310 |
| Borrowings + | 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 | 19 |
| Other Liabilities + | 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 205 | 174 |
| Total Liabilities | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 | 554 |
| Fixed Assets + | 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 57 | 53 |
| CWIP | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 84 | 113 |
| Other Assets + | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 416 | 387 |
| Total Assets | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 557 | 554 |
Financials of Anuh Pharma
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 16 | 26 | 2 | 7 | 49 | -19 | 29 | 54 | 13 | 37 | -3 |
| Cash from Investing Activity + | -12 | -5 | -20 | 2 | 3 | -77 | 52 | -8 | -43 | 1 | -20 | 18 |
| Cash from Financing Activity + | -8 | -9 | -4 | -5 | -7 | 22 | -33 | -19 | -12 | -9 | -5 | -26 |
| Net Cash Flow | -1 | 2 | 2 | -1 | 3 | -5 | 0 | 2 | -2 | 5 | 12 | -12 |
| Free Cash Flow | 18 | 6 | 25 | -5 | -22 | 13 | -25 | 27 | 52 | 8 | 17 | -11 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 96% | 78% | 149% | 49% | 56% | 232% | -20% | 80% | 130% | 42% | 78% | 16% |
Financials of Anuh Pharma
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 | 113 |
| Inventory Days | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 | 90 |
| Days Payable | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 | 114 |
| Cash Conversion Cycle | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 | 89 |
| Working Capital Days | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 | 92 |
| ROCE % | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% | 15% |
Guidance history
How Anuh Pharma's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY22 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY22 call → | 20–40% | Flat | Planned | — | — |
| Q2 FY22 call → | 20–40% | Flat | Planned | — | Rising |
| Q1 FY22 call → | 20–40% | Flat | Planned | — | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
29 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,937 stocks |
|---|---|---|
| Last 12 months | +0.2% | 54% |
| Last 6 months | +4.9% | 54% |
| Last 3 months | +8.2% | 76% |
The price is 35.5% below its all-time high of ₹127.78 (26 Apr 2024). Stocks more than 20% below their peak have their score halved, so 58 became 29.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,937 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Anuh Pharma: 0.4 × 54 + 0.4 × 54 + 0.2 × 76 = 58, halved to 29 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Anuh Pharma: frequently asked questions
What is Anuh Pharma share price today?
Anuh Pharma last traded at ₹82.45, with a market capitalisation of ₹819 Cr and a P/E ratio of 17.1.
What were Anuh Pharma's latest quarterly results?
For the quarter ended Sep 2026, Anuh Pharma reported revenue of ₹185 Cr (+0% year on year) and net profit of ₹11 Cr, with an operating margin of 9%.
Is Anuh Pharma's profit growing?
Net profit was ₹11 Cr in Sep 2026 against ₹8 Cr in Sep 2025, a change of +38%.
What is Anuh Pharma's EPS?
Anuh Pharma's earnings per share for the quarter ended Sep 2026 was ₹1.12.
What is the promoter holding in Anuh Pharma?
Promoters held 71.79% of Anuh Pharma in Sep 2026 (unchanged versus Jun 2026).
How much do FIIs and DIIs hold in Anuh Pharma?
In Sep 2026, foreign institutional investors held 0.11% and domestic institutions (including mutual funds) held 0.00% of Anuh Pharma.
What is Anuh Pharma's ROE and ROCE?
Anuh Pharma's return on equity is 11.3% and its return on capital employed is 14.9%.
Does Anuh Pharma pay a dividend?
Yes. Anuh Pharma's dividend yield is 1.81% at the current price. The full payout history is on the Anuh Pharma dividends page.
Which sector does Anuh Pharma belong to?
Anuh Pharma is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Anuh Pharma's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Anuh Pharma's management.
How does Arthneeti AI analyse Anuh Pharma?
Arthneeti reads Anuh Pharma's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
- Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
- Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F